Amsterdam, The Netherlands, May 22, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitted a response to the European Medicines Agency's (EMA) second Day 180 list of outstanding issues for ATIR101. Kiadis submitted a marketing authorization application (MAA) to the EMA in 2017 seeking approval of ATIR101 as an adjunctive immunotherapy for hematopoietic stem cell transplant (HSCT) in adults with late-stage blood cancer.

The second Day 180 List of Issues was focused on one remaining major observation. In drafting the company's response, Kiadis has thoroughly analyzed this observation and have created multiple analyses of existing clinical data to address this observation, including analyses of various (pooled) ATIR and historical control data.

"We received the EMA's day 180 second list of outstanding issues in the fourth quarter of 2018, and have spent the past few months conducting additional analysis of existing data to support our response," said Arthur Lahr, CEO, of Kiadis Pharma. "With this submission complete, we aim to receive an opinion from Committee for Medicinal Products for Human Use (CHMP) in 2019. If the CHMP opinion is positive, it would enable us to receive a conditional marketing approval from the European Commission, followed by commercial use of ATIR101 in a first patient in a European country at the end of 2019."

tijd 09.26
De Smallcap 981,81 -7,15 -0,72% Kiadis EUR 9,28 +21ct vol. 101.869